Study Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity

Trial Information

Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNervous SystemProduct ClassAntiepilepticsPharmacological SubgroupAntiepilepticsChemical SubgroupOther AntiepilepticsCondition StudiedObesity
Sponsor Protocol NumberCAPSS-220Enrollment407Data PartnerJohnson & Johnson% Female84.2%Mean/Median Age (Years)44% White75.7%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.